AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Continuing Medical Education (CME)

Accreditation Statement
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement
The AACR has designated this live activity for a maximum of 24.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey, below, by Monday, December 21, 2015. Certificates may be printed online after completing the Request for Credit Survey. 

Statement of Educational Need, Target Audience, and Learning Objectives
Molecularly targeted therapies have achieved great success from the "early days" of selective estrogen receptor modulators and aromatase inhibitors to more recent developments in signal transduction, histone deacetylases, and proteasome inhibitors. However, for each of these success stories, there are new challenges in terms of resistance, further refinement of these "targeted therapies" based on molecular sub-classification, and the opportunity to develop new combination therapies. 

Targeted cancer therapeutics allow practicing clinicians to tailor cancer treatment, especially when a target is present in some but not all tumors of a particular type. Eventually, treatments may be individualized based on the unique set of molecular targets produced by the patient's tumor. Targeted cancer therapies also hold the promise of being more selective for cancer cells than normal cells, thus harming fewer normal cells, reducing side effects, and improving quality of life.

Attendees at this program will be exposed to the latest research in the areas of cellular immunotherapy, mutation profiling, immune checkpoints and checkpoint blockade, targeting RAS, systems biology, radiomics, epigenetics, metabolism and the tumor microenvironment. Discussions from the podium, during the poster sessions, and the informal interactions throughout the conference will spur new collaborations and provide guidance on future treatment opportunities for patients.

After participating in this CME activity, physicians should be able to:

  1. Assess the state of therapeutic vaccines and their potential impact for cancer care.

  2. Explain the emerging field of cancer immunotherapy and the multiple avenues being researched for therapeutic application.

  3. Identify the latest advances in targeting RAS, DNA repair, and hormones in cancer and the potential for therapeutic applications.

  4. Demonstrate the usefulness of genetic data into clinical decision-making and effective treatment strategies.

  5. Interpret the potential for new imaging and omics technologies in early drug development.

Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR will provide information that Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the meeting app, online planner, and now available for download here.

Acknowledgement of Financial or Other Support
This activity is supported by grants which will be disclosed at the activity.

Questions About CME?
Please contact the Office of CME at 215-440-9300 or